Bita Fakhri

Internal Medicine
875 Blake Wilbur Dr
Palo Alto, CA 94304

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 48 publications

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial.

Journal: The Lancet. Haematology
Published: September 18, 2025

Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.

Clinical profiles of chronic lymphocytic leukaemia patients with SF3B1 mutations: A single-institution study.

Journal: British journal of haematology
Published: August 26, 2025

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R marginal zone lymphoma: phase 1/2 BRUIN study.

Journal: Blood advances
Published: June 18, 2025

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study.

Pirtobrutinib, a Highly Selective, Non-covalent (Reversible) BTKi in R/R Marginal Zone Lymphoma: Phase 1/2 BRUIN Study.

Journal: Blood advances
Published: June 18, 2025

Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.

Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.

Journal: Blood
Published: May 14, 2025

Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.

Oncogenic SF3B1 mutations alter the splicing of mRNA noncoding regions to induce a novel therapeutic vulnerability.

Journal: Blood
Published: May 14, 2025

Consensus in CLL: global needs matter.

Consensus in CLL: global needs matter.

Journal: Blood advances
Published: March 11, 2025

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Pirtobrutinib, a highly selective, noncovalent (reversible) BTKi in R/R follicular lymphoma: phase 1/2 BRUIN study.

Journal: Blood advances
Published: October 01, 2024

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.

Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.

Journal: American journal of hematology
Published: September 10, 2024

Pericardial events associated with ibrutinib-based therapies for chronic lymphocytic leukaemia in two landmark trials.

Pericardial events associated with ibrutinib-based therapies for chronic lymphocytic leukaemia in two landmark trials.

Journal: British journal of haematology
Published: June 03, 2024

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.

Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapy.

Journal: EJHaem
Published: May 16, 2024

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.

Journal: Haematologica
Published: April 26, 2024
Showing 1-12 of 48

Last Updated: 09/26/2026